DYNAVAX TECHNOLOGIES CORP (DVAX)
US2681582019 - Common Stock
Overall DVAX gets a fundamental rating of 5 out of 10. We evaluated DVAX against 564 industry peers in the Biotechnology industry. DVAX has an average financial health and profitability rating. DVAX has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
DVAX had positive earnings in the past year.
DVAX had a positive operating cash flow in the past year.
In multiple years DVAX reported negative net income over the last 5 years.
In multiple years DVAX reported negative operating cash flow during the last 5 years.
1.2 Ratios
DVAX has a better Return On Assets (1.93%) than 93.36% of its industry peers.
DVAX's Return On Equity of 3.01% is amongst the best of the industry. DVAX outperforms 94.08% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.93% | ||
| ROE | 3.01% | ||
| ROIC | N/A |
ROA(3y)12%
ROA(5y)-8.23%
ROE(3y)27.27%
ROE(5y)-384.92%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
DVAX's Profit Margin of 7.85% is amongst the best of the industry. DVAX outperforms 94.25% of its industry peers.
The Gross Margin of DVAX (82.85%) is better than 87.43% of its industry peers.
DVAX's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 7.85% | ||
| GM | 82.85% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.87%
GM growth 5YN/A
2. Health
2.1 Basic Checks
DVAX does not have a ROIC to compare to the WACC, probably because it is not profitable.
DVAX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, DVAX has more shares outstanding
The debt/assets ratio for DVAX has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 2.67 indicates that DVAX is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of DVAX (2.67) is better than 72.89% of its industry peers.
DVAX has a debt to FCF ratio of 9.85. This is a negative value and a sign of low solvency as DVAX would need 9.85 years to pay back of all of its debts.
DVAX has a Debt to FCF ratio of 9.85. This is amongst the best in the industry. DVAX outperforms 93.00% of its industry peers.
A Debt/Equity ratio of 0.33 indicates that DVAX is not too dependend on debt financing.
DVAX has a worse Debt to Equity ratio (0.33) than 71.45% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.33 | ||
| Debt/FCF | 9.85 | ||
| Altman-Z | 2.67 |
ROIC/WACCN/A
WACC10.17%
2.3 Liquidity
DVAX has a Current Ratio of 13.23. This indicates that DVAX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of DVAX (13.23) is better than 87.07% of its industry peers.
A Quick Ratio of 12.34 indicates that DVAX has no problem at all paying its short term obligations.
DVAX's Quick ratio of 12.34 is amongst the best of the industry. DVAX outperforms 85.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 13.23 | ||
| Quick Ratio | 12.34 |
3. Growth
3.1 Past
The earnings per share for DVAX have decreased strongly by -66.67% in the last year.
DVAX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -27.77%.
Measured over the past years, DVAX shows a very strong growth in Revenue. The Revenue has been growing by 95.18% on average per year.
EPS 1Y (TTM)-66.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
Revenue 1Y (TTM)-27.77%
Revenue growth 3Y70.82%
Revenue growth 5Y95.18%
Sales Q2Q%15.99%
3.2 Future
The Earnings Per Share is expected to grow by 118.95% on average over the next years. This is a very strong growth
Based on estimates for the next years, DVAX will show a very strong growth in Revenue. The Revenue will grow by 20.59% on average per year.
EPS Next Y293.24%
EPS Next 2Y151.47%
EPS Next 3Y118.95%
EPS Next 5YN/A
Revenue Next Year20.75%
Revenue Next 2Y20.28%
Revenue Next 3Y18.71%
Revenue Next 5Y20.59%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 99.54, the valuation of DVAX can be described as expensive.
Based on the Price/Earnings ratio, DVAX is valued cheaply inside the industry as 93.18% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of DVAX to the average of the S&P500 Index (27.41), we can say DVAX is valued expensively.
DVAX is valuated quite expensively with a Price/Forward Earnings ratio of 49.88.
Compared to the rest of the industry, the Price/Forward Earnings ratio of DVAX indicates a rather cheap valuation: DVAX is cheaper than 92.46% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.69, DVAX is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 99.54 | ||
| Fwd PE | 49.88 |
4.2 Price Multiples
DVAX's Price/Free Cash Flow ratio is rather cheap when compared to the industry. DVAX is cheaper than 93.36% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 74.98 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
DVAX's earnings are expected to grow with 118.95% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.34
PEG (5Y)N/A
EPS Next 2Y151.47%
EPS Next 3Y118.95%
5. Dividend
5.1 Amount
No dividends for DVAX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
DYNAVAX TECHNOLOGIES CORP
NASDAQ:DVAX (1/3/2025, 8:00:01 PM)
After market: 13 +0.06 (+0.46%)12.94
+0.04 (+0.31%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners103.75%
Inst Owner Change-3.58%
Ins Owners0.34%
Ins Owner Change0%
Market Cap1.70B
Analysts81.67
Price Target24.28 (87.64%)
Short Float %12.81%
Short Ratio7.36
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.49%
Min EPS beat(2)3.56%
Max EPS beat(2)21.41%
EPS beat(4)3
Avg EPS beat(4)-20.01%
Min EPS beat(4)-205.01%
Max EPS beat(4)100%
EPS beat(8)6
Avg EPS beat(8)96.03%
EPS beat(12)8
Avg EPS beat(12)88.23%
EPS beat(16)11
Avg EPS beat(16)49.38%
Revenue beat(2)0
Avg Revenue beat(2)-5.51%
Min Revenue beat(2)-6.08%
Max Revenue beat(2)-4.93%
Revenue beat(4)1
Avg Revenue beat(4)-4.27%
Min Revenue beat(4)-9.42%
Max Revenue beat(4)3.38%
Revenue beat(8)5
Avg Revenue beat(8)4.75%
Revenue beat(12)7
Avg Revenue beat(12)5.97%
Revenue beat(16)11
Avg Revenue beat(16)16.49%
PT rev (1m)0%
PT rev (3m)-2.86%
EPS NQ rev (1m)0%
EPS NQ rev (3m)660%
EPS NY rev (1m)0%
EPS NY rev (3m)-41.16%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)10.15%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.63%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 99.54 | ||
| Fwd PE | 49.88 | ||
| P/S | 6.52 | ||
| P/FCF | 74.98 | ||
| P/OCF | 62.39 | ||
| P/B | 2.5 | ||
| P/tB | 2.5 | ||
| EV/EBITDA | N/A |
EPS(TTM)0.13
EY1%
EPS(NY)0.26
Fwd EY2%
FCF(TTM)0.17
FCFY1.33%
OCF(TTM)0.21
OCFY1.6%
SpS1.98
BVpS5.18
TBVpS5.17
PEG (NY)0.34
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.93% | ||
| ROE | 3.01% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 7.85% | ||
| GM | 82.85% | ||
| FCFM | 8.7% |
ROA(3y)12%
ROA(5y)-8.23%
ROE(3y)27.27%
ROE(5y)-384.92%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.87%
GM growth 5YN/A
F-Score5
Asset Turnover0.25
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.33 | ||
| Debt/FCF | 9.85 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 99.85% | ||
| Cap/Sales | 1.76% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | 110.78% | ||
| Current Ratio | 13.23 | ||
| Quick Ratio | 12.34 | ||
| Altman-Z | 2.67 |
F-Score5
WACC10.17%
ROIC/WACCN/A
Cap/Depr(3y)167.43%
Cap/Depr(5y)165.59%
Cap/Sales(3y)1.64%
Cap/Sales(5y)22.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-66.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
EPS Next Y293.24%
EPS Next 2Y151.47%
EPS Next 3Y118.95%
EPS Next 5YN/A
Revenue 1Y (TTM)-27.77%
Revenue growth 3Y70.82%
Revenue growth 5Y95.18%
Sales Q2Q%15.99%
Revenue Next Year20.75%
Revenue Next 2Y20.28%
Revenue Next 3Y18.71%
Revenue Next 5Y20.59%
EBIT growth 1Y-120.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year105.66%
EBIT Next 3Y45.38%
EBIT Next 5YN/A
FCF growth 1Y-83.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-81.62%
OCF growth 3YN/A
OCF growth 5YN/A